Iovance Biotherapeutics
IOVA
243 hedge funds and large institutions have $3.88B invested in Iovance Biotherapeutics in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 92 increasing their positions, 88 reducing their positions, and 23 closing their positions.
64% more call options, than puts
Call options by funds: $50.3M | Put options by funds: $30.6M
48% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 23
4% more funds holding
Funds holding: 233 → 243 (+10)
5% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 88
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
4.17% less ownership
Funds ownership: 106.08% → 101.91% (-4.2%)
8% less capital invested
Capital invested by funds: $4.22B → $3.88B (-$332M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$38.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$34.5M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$25.9M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$20.9M |
| 5 |
FM
Frazier Management
Seattle,
Washington
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$160M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$32M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$31.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$24.1M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$22.6M |
IOVA Hedge Fund Activity: Q3 2021 in Review
243 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2021, worth a combined $3.88B — down 7.9% from $4.22B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IOVA positions and 23 closed out — a net gain of 11 holders — while 92 added to existing stakes and 88 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $38.8M. The largest seller was ARK Investment Management, cutting an estimated $160M.
- 243 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2021, up from 233 in Q2 2021.
- Funds reported $3.88B of Iovance Biotherapeutics stock for Q3 2021, down 7.9% quarter-over-quarter.
- 34 funds opened new Iovance Biotherapeutics positions in Q3 2021 and 23 closed out, a net change of +11 holders.
- The largest Iovance Biotherapeutics buyer in Q3 2021 was Wellington Management Group, an estimated $38.8M added.
- The largest Iovance Biotherapeutics seller in Q3 2021 was ARK Investment Management, an estimated $160M sold.
Based on aggregated 13F filings for Q3 2021.